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Abstract Adverse drug reactions (ADRs) can cause serious
health problems, as shown in studies about drug-related
hospitalizations. To build knowledge of and raise awareness
about ADRs among healthcare professionals, more educa-
tion in the field of ADRs and pharmacovigilance (PV) is
needed. No standard exists for teaching PV at universities for
medical, pharmacy, dentistry and nursing students, so a core
curriculum needs to be developed to teach important aspects
of PV to students. In September 2016, a stakeholders’
meeting was initiated on behalf of the World Health Orga-
nization (WHO) and organized by the Netherlands
Pharmacovigilance Centre Lareb. This meeting addressed
and agreed on the PV competencies students need to develop
and what key aspects of the subject should be taught. Five
key aspects were identified: understanding the importance of
PV in the context of pharmacotherapy, and preventing, rec-
ognizing, managing and reporting ADRs. Since time and
resources for PV education are limited, elements of theWHO
PV core curriculum for university teaching were designed to
be integrated into existing courses but can be used as a stand-
alone programme. The basis of and outline for the WHO PV
core curriculum for university teaching are addressed in this
paper. It is expected that PV competencies for students are
vital for their contribution to safe use of medicines in the
future. In addition, this article aims to stimulate discussion
on this subject and promote collaboration between univer-
sities, national PV centres and other stakeholders to integrate
key aspects of PV in their educational programmes.
Key Points
The World Health Organization (WHO)
pharmacovigilance (PV) core curriculum for
university teaching focusses on clinical aspects and
can be integrated into existing courses such as
pharmacology and pharmacotherapy or used as a
stand-alone course.
Key aspects of the WHO PV core curriculum for
university teaching are understanding the importance
of pharmacovigilance and preventing, recognizing,
managing, and—finally—reporting adverse drug
reactions.
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1 Introduction
Medicines help us treat many diseases, but adverse drug
reactions (ADRs) cause serious health problems. Studies
indicate that ADRs account for approximately 5% of all
acute hospitalizations [1–3]. About half of these hospital-
izations could have been prevented by more effective drug
therapy monitoring, timely recognition of the symptoms,
and knowledge about certain risk factors for occurrence of
these ADRs [1, 2]. From the patients’ perspective, all
ADRs are important. All ADRs can pose a problem and
may negatively influence quality of life and drug adher-
ence, irrespective of seriousness and whether they arise
from medication errors [4]. Sufficient knowledge of and
skills around the safety of medicines and safe use of drugs
in daily practice are important for all healthcare profes-
sionals (HCPs) who are directly involved in pharma-
cotherapy, such as doctors, pharmacists, dentists and
nurses, to reduce drug-induced patient harm [5].
Competence in handling ADRs in clinical practice is
important, not only for patient safety in individual patient
care but also for drug safety monitoring at a population
level. The science and activities relating to the detection,
assessment, understanding and prevention of adverse
effects or any other drug-related problem is called phar-
macovigilance (PV) [6]. Although medical and pharmacy
students may recognize the importance of ADR reporting
and express the intention to report ADRs, they are insuf-
ficiently prepared to handle ADRs and have inadequate PV
competencies [7–11]. This hampers optimal patient care
and the safe use of drugs now and in the future [7]. For
future HCPs to be competent in handling ADRs in clinical
practice and reporting them, more education is needed [12].
HCPs often consider ADR reporting to be an additional
activity rather than routine practice [13]. Beyond
improvement of PV education at the university level,
continuous educational interventions for practicing HCPs
have proven to be effective in PV competencies [14].
Besides education, inter-professional collaboration
improves the culture in healthcare in terms of recognizing
ADRs and the awareness of ADR reporting [15].
To acknowledge the importance of safety issues in
drug treatment, PV education should be introduced at an
early stage, along with patient care as part of the Hip-
pocratic Oath ‘‘first, do no harm’’. Since students are
accustomed to acquiring new knowledge and skills, it can
be expected that PV education of students at university
level will improve knowledge about safety of medicines
and skills for a safer use of medicines at an early stage of
their career [12, 16].
2 Development of a Practical Pharmacovigilance
(PV) Curriculum for University Teaching
To teach important aspects of PV to undergraduate stu-
dents, a core curriculum that describes desired competen-
cies and learning outcomes and provides practical materials
needs to be developed. Although patient safety, safe pre-
scribing and PV are increasingly recognized as important
topics in university educational frameworks worldwide, in
many countries this education depends on individual pro-
fessors or active PV centres [5, 12, 17–19].
Although there are initiatives to support education in the
field of patient safety and PV in general, there is no stan-
dard programme about PV for university teaching. In 2011,
the World Health Organization (WHO) established the
WHO Patient Safety curriculum for undergraduate stu-
dents. Although this curriculum contains medication errors
and related adverse events, some aspects related to PV are
still missing [20]. The WHO–International Society of
Pharmacovigilance (ISoP) curriculum for PV teaching,
designed for people interested in PV in any setting, consists
of a comprehensive list of topics that cover almost all
aspects of PV. Relevant topics for university teaching can
be selected by users, but practical information about
implementation of relevant sections of this curriculum and
ready-to-use-teaching materials and an undergraduate
course description should be developed [21, 22]. The
European programme in Pharmacovigilance and Pharma-
coepidemiology (EU2P) also offers education and training
in pharmacovigilance for individuals with a special interest
in PV [23]. For the broad audience of medical, pharmacy
and nursing students in general, a manageable curriculum
or programme is needed.
In September 2016, a stakeholder’s meeting was initi-
ated on behalf of the WHO, under its Programme of
International Drug Monitoring, and organized by The
Netherlands Pharmacovigilance Centre Lareb WHO Col-
laborating Centre for Pharmacovigilance in Education and
Patient Reporting. Meeting participants had backgrounds in
medical or pharmacy teaching, PV and governmental
positions and came from various continents (for details see
the co-author section). This meeting addressed and agreed
on the competencies in the field of PV students at univer-
sity level need to develop and the key aspects that should
be taught.
In this article, we outline the key aspects and compe-
tencies that form a PV core curriculum for university
education. The key aspects of PV can be integrated in
existing courses for medical, pharmacy, dentistry and
nursing education. The curriculum can also be used as a
stand-alone programme. To our knowledge, the WHO PV
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core curriculum for university teaching is the first to be
described in the literature.
3 Key Aspects of PV Education
PV entails various aspects of science and activities related
to the safety and safe use of medicines throughout the
entire lifecycle of a drug, from clinical research to post-
authorisation phase. It is strongly associated with both
regulatory aspects and clinical pharmacology. Since most
students will work in clinical practice and provide patient-
care services after graduation, our aim is to focus on the
clinical aspects of PV and the use of authorised drugs as
desired learning outcomes. The proposed key aspects,
formulated as learning outcomes of undergraduate PV
education, are as follows:
1. understanding the importance of PV in the context of
pharmacotherapy
2. preventing ADRs when possible
3. recognizing ADRs when they occur
4. managing ADRs
5. reporting ADRs.
The PV key aspects are summarized in Table 1 and
explained in more detail in the following sections, see also
Fig. 1.
3.1 Understanding the Importance of PV
in the Context of Pharmacotherapy
Awareness of the impact of ADRs on individual patients is
important for undergraduate students to understand
patients’ perspectives on safety issues. The stories of
patients who have experienced ADRs will elucidate the
impact of ADRs to students. Both serious and non-serious
ADRs may negatively influence patients’ quality of life and
treatment satisfaction and hamper drug compliance [24].
Students also need knowledge of the extent of drug-
induced harm at a population level, which can be visual-
ized using drug-related hospital admissions [1, 2] and with
historical examples of drug-induced disasters such as limb
deformities following maternal use of thalidomide [25].
These examples gave rise to the present-day regulatory
framework and the way in which the safety monitoring of
drugs is organized.
Table 1 Summary of the key aspects and content of the World Health Organization pharmacovigilance core curriculum for university teaching
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The WHO PV core curriculum for university teaching has five key aspects, which are the desired learning outcomes for future HCPs. Based on
Bloom’s taxonomy, learning objectives can be determined in a structured way. In its basic form, there are three categories of learning:
knowledge, skills and attitudes [35]. Knowledge, skills and attitudes for each learning outcome (key aspect) in the WHO PV core curriculum for
university teaching have been defined. Examples of teaching methods are added to the table for a complete overview of the WHO PV core
curriculum for university teaching
ADR adverse drug reaction, HCP healthcare professional, PV pharmacovigilance, WHO World Health Organization
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3.2 Preventing Adverse Drug Reactions (ADRs)
Safe and rational prescribing and dispensing of drugs
entails therapeutic reasoning and decision making, such as
choosing the right drug for each individual patient. The
occurrence of an ADR to previous treatment, as well as the
individual patient’s risk factors should influence this
choice. Students need to learn how to consider all cir-
cumstances that influence the occurrence of ADRs in a
patient. This implies knowledge of general risk factors,
such as the increased incidence of ADRs in the elderly, as
well as individual risk factors related to a certain drug or to
a person’s medical condition, such as comorbidity and
genetic factors. Drug–drug interactions can be expected
when patients use concomitant medication, especially in
polypharmacy [26], or when patients use herbal or other
traditional medicines [27]. Food–drug interactions may
influence drug absorption or drug metabolism; for example,
grapefruit juice inhibits drugs metabolized by cytochrome
P450 (CYP)-3A4 [28]. Information on these risk factors is
generally available in drug labelling, treatment guidelines
and medical literature, which students must learn to use
and interpret.
3.3 Recognizing ADRs
It is important that students learn how to recognize
symptoms of ADRs in patients. Identifying ADRs can be
difficult, because sometimes they are hard to distinguish
from underlying disease or comorbidity. This requires
knowledge of clinical pharmacological principles of ADRs,
such as types of ADRs, dose-relatedness, pharmacological
actions, hypersensitivity reactions, time relationship and
risk factors [29, 30]. Training in clinical reasoning with a
focus on causality reasoning is important to distinguish a
suspected ADR from other medical conditions or back-
ground incidence.
Observations of ADRs and designing individual treat-
ment plans for managing ADRs will strongly contribute to
the development of awareness of the impact of ADRs in
patients and on the importance of PV at a population level.
3.4 Managing ADRs
Patients who experience an ADR need special and indi-
vidual attention. The impact of ADRs ranges from absent
or mild influence on quality of life to life-threatening sit-
uations, such as anaphylaxis or intracranial haemorrhages.
Furthermore, ADRs may negatively influence a patient’s
compliance with therapy. Therefore, depending on the
indication, seriousness, perceived severity and prognosis,
patients and HCPs must design an individual treatment
plan. Actions for treatment include drug discontinuation,
dose adjustment or additional treatment of the symptoms.
Sometimes, alternative treatment for the initial disease
should be chosen. After experiencing a severe ADR,
patients might fear drug treatment in general [31]. Students
need the skills and knowledge to classify an ADR and the
competence to respond when they come across serious or
severe ADRs, which can be difficult.
Communication skills are also needed to better explain
safety data to colleagues and patients and encourage and
understand feedback from those involved in PV [32].
Students should furthermore develop the ability to
explain ADRs to patients and their families, advising about
future drug use and the chances of the ADR recurring [33].
Finally, relevant elements of the ADR should be
recorded properly into the patient’s healthcare record.
3.5 Reporting ADRs
Beyond the awareness of ADRs in individual patients, PV
also focusses on the improvement of public health
regarding the safety and safe use of medicines. Students
need to understand that information on ADRs from the pre-
marketing phase is limited. HCPs have a responsibility to









Understanding the importance of PV in pharmacotherapy (condion)
Report ADRs
(contribuon to paent and populaon safety)
Fig. 1 House of PV in clinical practice. The foundation of PV in
clinical practice is understanding the importance of PV in the context
of pharmacotherapy and creating awareness of occurrence of safety
issues during pharmacotherapy. Understanding the importance of PV,
as well as the awareness of ADRs, is conditional for recognition,
management and prevention of ADRs. These are the three main walls
of preventing drug-induced harm in patients. Experienced drug-
induced harm is a motive for reporting ADRs, shown here as the roof
of the house, as an individual’s contribution to increasing the
knowledge of ADRs and detecting new signals of potential risks.
Knowledge of ADRs provides more insight into the occurrence of
ADRs in patients, which can be used directly in clinical practice. ADR
adverse drug reaction, PV pharmacovigilance
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with regulatory authorities. Spontaneous reporting systems
continue to be an effective method of signal detection [34].
ADR reports from HCPs and patients often trigger the
detection of potential new medicines safety signals. They
improve general information about ADRs. Reporting an
ADR to PV centres or other relevant organisations is a skill
that can be developed easily during clinical internships
[4, 32].
4 Integration of PV Key Aspects in Existing
Educational Programmes
4.1 PV Competencies for Future Healthcare
Professionals
Competency-based educational models are becoming more
dominant than the traditional content-driven and teacher-
centred learning methods in university teaching [36, 37]. A
competency can be described as an individual’s ability to
make deliberate choices for handling situations and tasks in
specific contexts of professional practice [36]. In the con-
text of pharmacotherapy, competencies in PV are the
timely recognition, prevention and management of ADRs.
To acquire competencies, different learning outcomes
with skills, knowledge and attitudes can be defined [35].
Competencies in PV were first described by Edwards et al.
[32] in 2006. In the broad context of professional PV,
healthcare professionals in clinical practice must ensure the
safe use of drugs and contribute to the reporting of ADRs.
We summarized learning outcomes regarding these
competencies as key PV aspects (Table 1). Students
develop different levels of competence throughout their
educational career, which require adjusted and aligned
learning activities. Figure 2 illustrates how the related key
PV aspects can be divided into levels of competence
throughout university education. By offering key PV
aspects with increasing complexity at different stages of
education, students will acknowledge the importance of the
subject and will be challenged and motivated to learn.
4.2 Practical Aspects
The importance of PV can be taught from the first year of
education, since limited specific knowledge is required.
The clinical aspects of PV can be considered logical
extensions of general subjects such as pharmacology and
toxicology. The actual recognition, management and pre-
vention of ADRs therefore requires broad knowledge and
skills from pharmacology, pharmacokinetics, pathophysi-
ology, pharmacotherapy, drug development, pharmaceuti-
cal regulations, epidemiology and general science. This
implies the integration of key PV aspects becomes feasible
later on in the Bachelor or Master phases, depending on the
MASTER: The student …..
….. is able to an cipate on poten al adverse drug reac ons when prescribing or designing
a pharmacotherapeu treatment plan for an individual pa t;
..… is able to recognize and interpret (expected and unexpected) adverse drug
reac ons, occurring in real-life pa ts;
..… is able to design eﬀec ve treatment interven ons for pa ts, suﬀering from
adverse drug reac ons;
….. is able to report adverse drug reac ons to the locally recognized authori s.
BACHELOR: The student…..
….. is able to iden y adverse drug reac ons in authen c descrip ons or examples
of (rela vely simple) pa t cases;
….. is able to explain the mechanism of rela vely simple adverse drug reac ons in terms
of pharmacological, toxicological principles and/or individual risk factors;
….. is able to suggest pharmacotherapeu interven ons for rela vely simple cases of
adverse drug reac ons.
YEAR 1: The student …..
….. knows the concept ‘pharmacovigilance’ and is able to describe the importance of 
preven , recognizing, managing and repor adverse drug reac ons;
..… is able to give historical and current examples of drug-induced harm.
Fig. 2 Example of curriculum
levels of competence in PV
education. The pyramid shows
increasing complexity of key
PV aspects during university
education. Depending on the
local situation and structure of
the educational programme, a
Bachelor/Master division may
be absent. Apart from the
structure, increasingly complex
learning outcomes can be
offered throughout the
programme. ADR adverse drug
reaction, PV
pharmacovigilance. Adapted
from Koster et al. [36]
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local structure of educational programmes. The actual
reporting of an ADR needs a real clinical context, which is
offered at the end of most educational programmes.
As demonstrated by Hartman et al. [12] and Schutte
et al. [7], the time for education on PV appears to be
limited. The amount of contact hours for explicit PV
education in medical, pharmacy and nurse education was
about 2–5 h in the entire curriculum [12]. The limited time
and the applicability in clinical practice forces the PV core
curriculum for university teaching to be confined to clinical
aspects. The multidimensional character of PV education
requires integration of key aspects in existing pharma-
cotherapy courses or methods such as prescribing safety
assessments (PSA) [38]. In PSA, the evaluation of pre-
venting, recognizing and managing ADRs should be
incorporated as defined by the Guide to Good Prescribing
[39].
4.3 PV in Educational Frameworks
Educational frameworks and medical codes of conduct
provide a formal basis on which to integrate PV aspects
into existing curricula [18]. For pharmacy and medical
students, preventing and handling ADRs, as well as
reporting ADRs to national PV centres, are listed in the
frameworks [17, 40–43]. In Europe, a set of 252 learning
outcomes for clinical pharmacology and therapeutics
(CPT) education was published recently to harmonize
medical education. The key PV aspects are covered in the
description of the CPT learning outcomes [19].
Preventing, recognizing and managing ADRs and PV
elements are lacking in educational frameworks for nurses
everywhere, although patient safety in general is regarded
as an important topic [44, 45]. Furthermore, it has been
shown that nurses are thoroughly capable of recognizing
and reporting ADRs [5, 46].
5 Examples of Undergraduate PV Education
The ways in which PV is taught differs according to
country [12]. In some European countries, PV has been
integrated at a high level in therapeutics courses or pro-
grammes such as PSA [18]. In developing countries,
pharmacotherapy education has its own challenges, and PV
is less well developed, both in general and in education
[47]. A few examples of PV educational methods at uni-
versities are described in the literature and summarized in
Table 2. Most of these examples show active learning
elements, such as developing a reporting form, reporting an
actual ADR, assessing causality of ADR reports, problem-
based learning and group discussions. Active and contex-
tual educational methods have proven to be effective ways
of transferring knowledge [48]. However, education is
currently almost exclusively aimed at ADR reporting.
Studies have demonstrated that educational interventions
for HCPs about PV positively influenced ADR reporting in
the short term [14, 49–52]. There are no long-term studies
of the PV competencies of university students after
graduation.
Table 2 Examples of methods in pharmacovigilance education at university level, ordered in type of students, educational phase and kinds of
learning activities
Method Students Phase Learning activities Countries








PV course Pharmacy Bachelor 3rd year Lectures, causality assessment,




ADR assessment Medical Bachelor/Master ADR report analysis Netherlands [60]
ADR problem solving Medical Bachelor Problem solving Netherlands [61]
Safe prescribing Medical and nurse 4th year Interprofessional learning USA [15]
Pharmacology course: risk
perception of ADRs
Medical Bachelor 3rd year Clinical training France [62]
PV in pharmacoepidemiology
course
Biology and pharmacology Not provided Problem-based learning Canada [63]
ADR adverse drug reaction, PV pharmacovigilance
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In this WHO PV core curriculum for university teach-
ing, we propose a shift from a regulatory focus, which has
ADR reporting as a main learning outcome, to a more
healthcare-focussed approach. Such a clinical approach
integrates key PV aspects into existing pharmacology
education programmes, with the aim of decreasing drug-
induced harm in patients. We believe that awareness of the
impact of ADRs stimulates students’ interest in PV. It
could be expected that students are motivated to report in
future if they regard ADRs and PV as important topics.
Active learning methods are preferred over passive
learning methods such as lectures to obtain competences
[36]. Authentic learning activities that prepare students for
their professional tasks can motivate learning. Case studies,
problem-based learning, simulations, the use of
entrustable professional activities and internships at PV
centres can be effective [36]. Methods can be adjusted
according to each country’s situation.
6 Conclusion and Future Steps
This paper provides an outline of the WHO PV core cur-
riculum for university teaching, in which competencies and
key aspects of PV for future HCPs have been formulated.
In today’s busy clinical practice, drug-related problems
such as the prevention, recognition and management of
ADRs do not always get the attention they need. When
students are competent at preventing, recognizing and
managing ADRs, they can and will improve the safe use of
drugs.
Since PV is important for all HCPs in clinical and public
health disciplines, key PV aspects should be integrated into
existing programmes and courses for medical, pharmacy,
dentistry and nursing education. We emphasise that the key
PV aspects are intended to be add-in elements. Therefore,
we expect that integrating PV elements into existing
courses requires a limited time investment.
As a first step, universities would need to recognize
possible gaps in their educational programmes and provide
opportunities for teachers to integrate elements of the PV
core curriculum for university teaching. National PV cen-
tres or other PV stakeholders can stimulate and facilitate
PV education for students. For example, they can provide
‘teach the teacher’ courses to train university teachers
about PV. Second, in countries where reporting ADRs is a
challenge, PV education at a university level can take place
in parallel with improving the reporting system.
Further discussions are needed to develop materials and
share experiences to integrate key PV aspects in university
teaching. A second stakeholder meeting was held in 2017
to discuss materials, teaching methods and strategy for
sharing and implementation. Participants from the second
meeting came from various parts of the world and are
actively involved in PV education at universities, as PV
staff or as university teachers. The main outcomes were to
develop a web portal for sharing materials and to construct
a ‘teach the teacher’ programme to promote PV education
to university staff who are less familiar with PV.
To meet PV competencies in clinical practice, a cultural
change is required in healthcare institutions in which PV is
not yet common practice. The number of pharmaceutical
products is increasing, as is the number of patients across
the world with access to these treatments. The central role
for PV, aiming at the safety and safe use of medicines, is
fundamental for future HCPs. By developing PV compe-
tencies at universities, we may take the first step in this
journey of change.
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